Reply to zur Wiesch and van Lunzen

Journal of Infectious Diseases

Volumn 208, Issue 2, 2013, Pages 363-

  Azzoni, Livio ^a   Foulkes, Andrea S ^b   Papasavvas, Emmanouil ^a   Mexas, Angela M ^c   Lynn, Kenneth M ^a,d   Mounzer, Karam ^e   Tebas, Pablo ^d   Jacobson, Jeffrey M ^f   Frank, Ian ^d   O'Doherty, Una ^c   Kostman, Jay ^d   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c Pathology and Laboratory Medicine   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Jonathan Lax Treatment Center   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2A; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INNATE IMMUNITY; LETTER; LYMPHOCYTE FUNCTION; MONOTHERAPY; PRIORITY JOURNAL; SUSTAINED VIRAL RESPONSE; VIRAL CLEARANCE; VIREMIA; VIROLOGY; VIRUS REPLICATION; DRUG EFFECT; FEMALE; MALE; NOTE; VIRUS DNA CELL DNA INTERACTION;

ANTIVIRAL AGENTS; FEMALE; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84879354406     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit160     Document Type: Letter

References (9)

1. Pillai SK, Abdel-Mohsen M, Guatelli J, et al. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV- 1 in vivo. Proc Natl Acad Sci U S A 2012; 109:3035-40
2. Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, Carr WH. Changes in natural killer cell activation and function during primary HIV-1 infection. PLoS One 2013; 8: e53251
3. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-6
4. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012; 17:1001-9
5. Boue F, Reynes J, Rouzioux C, et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS 2011; 25:115-8
6. Schulze Zur Wiesch J, Pieper D, Stahmer I, et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 2009; 49:466-72
7. Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012; 26:1895-905
8. Meier UC, Owen RE, Taylor E, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 2005; 79:12365-74 (Pubitemid 41346098)
9. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.